A randomized study of solriamfetol for excessive sleepiness in narcolepsy.

Ann Neurol · 2019 · PMC6593450 · PMID 30694576

Europe PMC DOI

hedged sentence

0.0023

closest p · 0.0× alpha

0.0023

boldest claim

The sentences

nominally significantp = 0.0023actually significant

At week 12, these increases were dose‐dependent and were significant for solriamfetol 300 mg (84.7%) and 150 mg (78.2%) doses versus placebo (39.7%; both p < 0.0001); the 75 mg dose was nominally significant (67.8%) compared with placebo ( p = 0.0023, but the comparison was below the hierarchical break).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.